Methylenedioxymetamfetamine - Mindmed
Alternative Names: 3,4-Methylenedioxymethamphetamine - MindMed; ecstasy - MindMed; MDMA - MindMed; Methylenedioxymetamphetamine - MindMed; Methylenedioxymethamfetamine - MindMed; Methylenedioxymethamphetamine - MindMed; Midomafetamine - MindMedLatest Information Update: 29 Aug 2024
At a glance
- Originator The University Hospital of Basel
- Class Amines; Amphetamines; Anxiolytics; Behavioural disorder therapies; Benzodioxoles; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mood disorders; Substance-related disorders
Most Recent Events
- 18 Jun 2024 The University Hospital, Basel completes a phase I trial in healthy volunteers in Switzerland (NCT04847206)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Mood disorders(In volunteers) in Switzerland (PO)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Substance-related disorders(In volunteers) in Switzerland (PO)